Searchable abstracts of presentations at key conferences in endocrinology

ea0090rc8.5 | Rapid Communications 8: Calcium and Bone | ECE2023

Treatment of chronic hypoparathyroidism by Eneboparatide, a novel PTH receptor-1 agonist: Results from a phase 2a study

Istvan Takacs , Mezozi Emese , Soto Alfonso , Kamenicky Peter , Figueres Lucile , Angeles Galvez Moreno M. , Lemoine Sandrine , Borson-Chazot Francoise , Capel Ismael , Ovize Michel , OuldRouis Taha , Allas Soraya , Sumeray Mark , Mannstadt Michael

Background: Conventional therapy for chronic hypoparathyroidism (cHP) is often unable to maintain stable normal serum calcium (Ca) levels for a full 24 h, to control symptoms, to prevent the detrimental long-term effects on the kidney and to preserve normal bone architecture. Eneboparatide (AZP-3601) is a novel 36-amino-acid peptide specifically designed to activate the R0 conformation of the PTH receptor 1, that results in a prolonged calcemic response and a sustai...